Ketamine

Dose and frequency dominate the detection window. A single recreational insufflation may produce only 24–48 hours of urinary detection, while chronic users — particularly those with ketamine-induced cystitis presenting after months of high-dose use — can remain positive for one to two weeks after the last exposure. The norketamine metabolite, produced by hepatic N-demethylation, extends the window meaningfully beyond what parent ketamine alone would provide, which is why modern ketamine immunoassays are designed to detect norketamine in addition to parent drug. Plasma elimination half-life for racemic ketamine is roughly 2–4 hours, with norketamine extending several hours longer; in urine the practical detection window is governed by metabolite excretion rather than by the short parent half-life.

Route of administration changes pharmacokinetics. Intravenous and intramuscular ketamine produce rapid peaks and rapid declines; intranasal esketamine (Spravato) follows a more controlled absorption curve dictated by its labeled dosing schedule; oral ketamine, used in some off-label clinical protocols, undergoes extensive first-pass metabolism that increases the relative ratio of norketamine to parent in urine. Insufflated recreational ketamine sits between intravenous and oral in absorption profile. Programs interpreting parent-to-metabolite ratios should be aware that ratio is route-dependent, and confirmation laboratories will sometimes annotate the ratio in their report to give the reviewing clinician context for whether a result is consistent with a single recent dose or with sustained dosing.

Hepatic metabolism via CYP3A4 (and to a lesser extent CYP2B6 and CYP2C9) governs ketamine clearance. CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John\'s wort can shorten the detection window; inhibitors such as ketoconazole, itraconazole, clarithromycin, and ritonavir may extend it. Significant hepatic impairment from cirrhosis, NASH, or active hepatitis also prolongs clearance. Norketamine is further metabolized to dehydronorketamine, a long-lived urinary marker that some specialty laboratories quantify for retrospective exposure assessment. Drug-drug interactions are not academic in clinical-monitoring contexts — patients on protease inhibitors, antifungals, or antiepileptics may show ketamine pharmacokinetics that diverge substantially from the textbook profile.

Renal function affects metabolite excretion, and body composition, urinary pH, age, and genetics contribute smaller modifying effects. Ketamine is moderately lipophilic, so higher adiposity can extend tissue redistribution and modestly prolong detection in chronic users. Urinary acidification tends to increase the fraction of parent ketamine eliminated unchanged; alkalinization tends to favor reabsorption and metabolite excretion. Age-related declines in renal and hepatic function in older donors, and immature elimination pathways in pediatric forensic cases, both shift detection. None of these are large effects compared with dose, route, and hepatic clearance, but they can shift detection at the margin and should be considered when interpreting a result that falls close to the cutoff or that diverges from clinical expectation, particularly in chronic-illness and geriatric populations.

Ketamine is NOT included in the SAMHSA Mandatory Guidelines for federal workplace drug testing, and the Department of Transportation panel — which follows the SAMHSA Mandatory Guidelines — does not include ketamine either. The SAMHSA-5 covers marijuana, cocaine, amphetamines (including MDMA), opiates, and PCP. Federally regulated programs that wish to screen for ketamine must add it as a non-SAMHSA analyte through a separate, non-regulated panel, and non-federal programs are free to include or exclude it as their use case requires. Many non-regulated workplace programs, hospital occupational-health departments, and substance-use treatment clinics deploy ketamine on a CLIA-waived multi-analyte device specifically to close this gap.

Industry-standard cutoffs for commercial ketamine urine immunoassays are typically 50–100 ng/mL for the initial screening test, with 50 ng/mL the most common confirmation cutoff by LC-MS/MS. Some specialty assays screen at lower cutoffs (25 ng/mL) for clinical pain-medicine and behavioral-health monitoring where therapeutic dosing produces predictable urinary concentrations. Magenta panels that include ketamine screen at the industry-standard cutoff; programs should verify the specific cutoff printed in the package insert of the device they deploy. A presumptive positive on the immunoassay is exactly that — presumptive — and any result intended to support clinical, employment, or legal action should move to confirmation by LC-MS/MS in a SAMHSA-certified or forensic-accredited laboratory before being reported as verified.

Patients receiving Spravato (esketamine) or intravenous ketamine for treatment-resistant depression will produce positive ketamine immunoassay results during the active treatment window and for several days after each dose. A Medical Review Officer reviewing a confirmed positive should request prescription history, REMS enrollment, dosing schedule, and the treating clinic\'s documentation before issuing a verified result. Quantitative LC-MS/MS confirmation that includes the parent-to-norketamine ratio can help corroborate the dosing pattern described by the donor. The MRO step is what distinguishes a defensible verified result from a raw analytical positive, and it is the operational checkpoint where therapeutic exposure is reconciled with legitimate prescription documentation.

Ketamine urinary immunoassays use the same lateral-flow competitive-binding format as Magenta\'s other point-of-care analytes. Sample wicks across a nitrocellulose membrane carrying immobilized ketamine conjugate; antibody bound to colored particles in the conjugate pad will either capture analyte from the sample or, if no analyte is present, bind the immobilized conjugate and produce a visible test line. The antibody is raised against ketamine, with most contemporary devices also detecting norketamine to extend the effective detection window. Read times are typically five minutes, and the result is interpreted identically to other analytes: absent test line indicates positive at the device cutoff, visible test line indicates negative, and an absent control line invalidates the device and requires recollection.

Cross-reactivity with structurally related compounds varies by manufacturer. Some ketamine immunoassays cross-react with phencyclidine (PCP) and with the veterinary anesthetic tiletamine; others are specifically calibrated to avoid PCP cross-reactivity so that ketamine and PCP can be reported as separate analytes on the same device. Cross-reactivity with dextromethorphan, a structurally related dissociative widely used in over-the-counter cough preparations, is generally low at clinical concentrations but appears in some assay-specific package-insert tables. Methoxetamine and other arylcyclohexylamine designer dissociatives may produce variable cross-reactivity. Programs that depend on distinguishing ketamine, PCP, and dextromethorphan should review the insert before standardizing on a device and document the chosen device in their standard operating procedure.

False positives from common non-dissociative medications are rare. The ketamine molecule is structurally distinct from most other classes, so cross-reactivity with opioids, benzodiazepines, stimulants, SSRIs, SNRIs, antipsychotics, and antihypertensives is essentially zero at routine clinical concentrations. This makes a ketamine screening positive a relatively high-specificity finding, though confirmation by LC-MS/MS remains appropriate before any adverse clinical or employment action is taken on the basis of a screen alone. Programs should resist the temptation to treat the immunoassay result as definitive — the regulatory and litigation history of workplace drug testing consistently rewards programs that follow the screen-then-confirm-then-MRO sequence.

Confirmation by LC-MS/MS is the gold standard. SAMHSA-certified laboratories quantify ketamine and norketamine independently, and the parent-to-metabolite ratio can be informative for distinguishing recent single use from sustained or repeated dosing. For patients receiving Spravato or off-label intravenous ketamine, the confirmation report should be reviewed by a Medical Review Officer alongside the treating clinic\'s documentation and dosing schedule. Quantitative results also support clinical decisions in pain-medicine programs that use ketamine therapeutically. The immunoassay-to-confirmation gap is the single most important operational concept for a program administrator to understand — the screen flags specimens for further work, but only the confirmation supports a defensible adverse action.

Specimen integrity testing applies to ketamine screens as it does to other analytes. Creatinine, specific gravity, pH, and oxidant adulterant panels (nitrite, chromate, glutaraldehyde, pyridinium chlorochromate, peroxidase) should accompany every ketamine screen. Donors with ketamine-induced cystitis may produce specimens with unusual integrity parameters because of inflammation and altered urinary chemistry; handling protocols should provide for repeat collection in those cases rather than immediate classification as a refusal to test. Observed collection — required for federally regulated post-accident and return-to-duty testing, and increasingly used in court-mandated, probation, and substance-use treatment settings — substantially reduces the risk of substitution or dilution and should be considered for any ketamine program where the consequences of a missed positive are high. Chain-of-custody documentation from collection through laboratory receipt is the backbone of any defensible result.